PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 100 filers reported holding PMV PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $24,132 | +205.5% | 14,896 | +220.6% | 0.00% | – |
Q1 2024 | $7,898 | -73.2% | 4,646 | -51.1% | 0.00% | – |
Q4 2023 | $29,475 | +124.3% | 9,508 | +344.3% | 0.00% | – |
Q3 2023 | $13,139 | +115.3% | 2,140 | +119.5% | 0.00% | – |
Q2 2023 | $6,104 | +67722.2% | 975 | -45.5% | 0.00% | – |
Q1 2023 | $9 | -91.4% | 1,788 | -85.2% | 0.00% | -100.0% |
Q4 2022 | $105 | -100.0% | 12,092 | -51.0% | 0.00% | -20.0% |
Q3 2022 | $294,000 | +46.3% | 24,694 | +75.1% | 0.01% | 0.0% |
Q2 2022 | $201,000 | +773.9% | 14,102 | +1199.7% | 0.01% | – |
Q1 2022 | $23,000 | -89.7% | 1,085 | -88.8% | 0.00% | -100.0% |
Q4 2021 | $224,000 | +113.3% | 9,680 | +173.6% | 0.00% | +33.3% |
Q3 2021 | $105,000 | +200.0% | 3,538 | +241.8% | 0.00% | +200.0% |
Q2 2021 | $35,000 | -61.5% | 1,035 | -62.7% | 0.00% | -50.0% |
Q1 2021 | $91,000 | +237.0% | 2,772 | +531.4% | 0.00% | +100.0% |
Q4 2020 | $27,000 | – | 439 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |